Xact Kapitalforvaltning’s Theravance Biopharma TBPH Stock Holding History

Xact Kapitalforvaltning’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$201K	Hold	8,716	–	–	﹤0.01%	1196
2019 Q4	$226K	Buy	+8,716	New	+$169K	﹤0.01%	1346
2019 Q1	–	Sell	-8,716	Closed	-$223K	–	1540
2018 Q4	$223K	Hold	8,716	–	–	0.01%	1394
2018 Q3	$285K	Buy	+8,716	New	+$238K	0.01%	1393
2018 Q2	–	Sell	-8,316	Closed	-$202K	–	1591
2018 Q1	$202K	Buy	+8,316	New	+$228K	﹤0.01%	1484

Other funds holding TBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFS

Link Fund Solutions London, United Kingdom $157M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Xact Kapitalforvaltning's TBPH Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Theravance Biopharma (TBPH) position steady in Q1 2020 at 8,716 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #1196.

Xact Kapitalforvaltning first reported a position in TBPH in Q1 2018 and has held it in 5 quarters since. The position peaked at $285K in Q3 2018. 105 funds tracked by Wall St. Rank hold TBPH as of Q1 2020.

Xact Kapitalforvaltning held 8,716 shares of Theravance Biopharma worth $201K as of Q1 2020.
Xact Kapitalforvaltning left its Theravance Biopharma share count unchanged in Q1 2020.
Theravance Biopharma made up ﹤0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #1196 holding.
Xact Kapitalforvaltning first reported a position in Theravance Biopharma in Q1 2018 and has held it in 5 quarters since.
Xact Kapitalforvaltning's Theravance Biopharma position peaked at $285K in Q3 2018.
105 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.